ReviewVascular health and risk management2016

Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.

Sanjiv GuptaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.